oxybutynin Tablets 5 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #31580
Established in 1990, this Indian manufacturer employs approximately 3,065 individuals and specializes in developing and manufacturing IP-led niche finished dosage formulations. As a CTD dossier owner and manufacturer, it holds GMP certifications from major regulatory authorities, including the US FDA, EU-GMP, Health Canada, and UK MHRA, ensuring compliance with stringent international quality standards. The company operates eight manufacturing units across India, Singapore, Italy, the United States, and Kenya, producing a range of products, including soft gelatin capsules, tablets, and ointments. As a CTD dossier owner and manufacturer, its products are distributed in over 100 countries worldwide.
Manufacturer usually replies in 2 days
Oxybutynin is a medication used to treat overactive bladder. Suppliers market it as oxybutynin oral tablets, transdermal patches, topical gels and it is available as immediate and delayed-release formulations.
The drug was first approved for medical use in 1975, and by now has reached widespread use, with over 6 million prescriptions registered yearly in the U.S. alone. Multiple manufacturing companies and drug vendors populate the global oxybutynin market, including major suppliers such as Sanofi-Aventis, Mylan, Accord Healthcare, and many others.
Suppliers market both generic and trade name oxybutynin medications. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 60 (5mg) tablets of oxybutynin fall into an approximate range of 7.50 EUR to 10.00 EUR.